SCHEMBL4199736

SCHEMBL4199736

CCOC(=O)c1nn2c(c1O)C(=O)N(C)CC2c1csc(C)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.36
GABRA5 P31644 2/20 0.36
MAPT P10636 5/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
FOS P01100 1/20 0.34
JUN P05412 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
KDM4E B2RXH2 5/20 0.33
OPRM1 P35372 4/20 0.33
OPRK1 P41145 4/20 0.33
OGFRL1 Q5TC84 4/20 0.33
ALDH1A1 P00352 4/20 0.33
OPRD1 P41143 3/20 0.33
ADORA1 P30542 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4200803 0.85 GABRA1 (0.35) GABRA1GABRA5MAPTSMN1; SMN2GABRG2
SCHEMBL4198619 0.83 MEN1 (0.36) GABRA1GABRA5MAPTSMN1; SMN2GABRG2
SCHEMBL13947742 0.77 SMN1; SMN2 (0.43) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4207843 0.69 MAPK1 (0.35) GABRA1GABRA5MAPTSMN1; SMN2GABRG2
SCHEMBL4198917 0.66 RIPK1 (0.40) MAPTKDM4EKMT2A
SCHEMBL4204607 0.61 ACE (0.40) GABRA1GABRA5SMN1; SMN2GABRG2GABRB3
SCHEMBL28492842 0.61 RIPK1 (0.47) MAPTSMN1; SMN2KDM4EALDH1A1HSD17B10
SCHEMBL914552 0.60 RAB9A (0.68) MAPTSMN1; SMN2ALDH1A1MEN1PKM
SCHEMBL14060102 0.60 GPR88 (0.44) MAPTSMN1; SMN2ALDH1A1HSD17B10MEN1
SCHEMBL14149184 0.60 GPR88 (0.44) MAPTSMN1; SMN2ALDH1A1HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758585-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-07-22 EP disclosed
US-7476666-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-01-13 US disclosed
US-20080015187-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-17 US disclosed
EP-1758585-A2 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2007-03-07 EP disclosed
WO-2005120516-A2 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015187-A1 Hiv Integrase Inhibitors REV1, ZC3HAV1, PNP GABRA1 2247/4885GABRA5 2962/4885MAPT 3777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.